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ABSTRACT 70 
 71 
Objective: We investigated the effects of the EVASYON programme on body fatness, 72 
cardiometabolic risk factors, gut appetite-controlling hormones and serum levels of cytokines 73 
in adolescents with overweight or obesity (OW/OB). Methods: The study comprised 13 boys 74 
(10 obese) and 12 girls (8 obese), aged 13 to 16 years, from a Madrid Hospital. The 75 
EVASYON programme was based on a calorie-restricted diet (10-40%), increased physical 76 
activity (at least 60 min/day 5 days a week), psychological therapy and nutritional education 77 
for 13-month. Anthropometric and blood pressure measurements were measured before and 78 
after intervention. Serum glucose, total cholesterol, high-density lipoprotein cholesterol, 79 
triglycerides, leptin, total peptide YY and insulin levels were determined before and after 80 
intervention. Serum levels of cytokines IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10 and TNF- 81 
were also assessed before and after intervention. Results: A decrease in body mass index 82 
(BMI), BMI z-score, skinfolds (triceps, biceps, subscapular, thigh, and calf), sum of 6 83 
skinfolds and body circumferences (arm relaxed and flexed, waist, hip and proximal thigh) 84 
values were observed after the intervention programme (all P<0.05). In addition, diastolic 85 
blood pressure also decreased (P<0.05). A decrease in serum leptin levels (–48.4%, P<0.001) 86 
was observed after intervention without changes in total peptide PYY and insulin levels. 87 
Levels of IL-8, IL-10 and TNF- also decreased (all P<0.05) after the intervention 88 
programme. Conclusions: These preliminary results evidence that the EVASYON 89 
programme may improve body fat, leptin, and some pro-inflammatory cytokines in 90 
adolescents with OW/OB.  91 
 92 
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INTRODUCTION 95 
Obesity is the most prevalent metabolic disease in adult humans, which has been 96 
associated with cardiometabolic risk factors, such as low-grade inflammation, insulin 97 
resistance, hypertension and dislipidemia (1,2). Since some of these cardiometabolic risks 98 
have been already identified in obese children and adolescents, early obesity underlies the 99 
metabolic groundwork for adult cardiovascular diseases (3-6).  100 
In this context, adipose tissue is a rich source of many immune-related mediators (e.g. 101 
cytokines such as tumour-necrosis factor-alpha [TNF-] and interleukin-6 [IL-6]) that are 102 
involved in the inflammatory response (4-6), mediating cardiometabolic disorders (7). 103 
Furthermore, adipose tissue is currently regarded as an active endocrine organ that, since in 104 
addition to regulating fat mass and energy homeostasis, it releases a large number of bioactive 105 
mediators modulating appetite and metabolism (8). Some of these bioactive mediators are 106 
hormones called adipokines and include leptin, adiponectin, peptide YY (PYY), among others 107 
(9,10). Recent data also suggest that these hormones have immunomodulating effects 108 
involving inflammatory processes (8-10).  109 
In this sense, the EVASYON (Development, implementation and evaluation of the 110 
efficacy of a therapeutic programme for adolescents with overweight and obesity: integral 111 
education on nutrition and physical activity) programme comprised a long-term intervention 112 
with calorie-restricted diet, physical activity, psychological therapy and nutritional education 113 
in adolescents with overweight or obesity (OW/OB) in hospital settings from Spain. Since 114 
inflammation associated with obesity declines after weight loss in adults (4), we hypothesized 115 
that a programme aimed to lose fat mass might modify specific obesity-associated markers of 116 
inflammation in adolescents. Therefore, this preliminary study was performed to characterize 117 
the effects of the EVASYON treatment programme on body fat, cardiometabolic risk factors, 118 
gut appetite-controlling hormones and cytokines levels in adolescents with OW/OB.  119 
METHODS AND PROCEDURES  120 
Study design and participants 121 
The EVASYON study is a multidisciplinary treatment programme study conducted in 122 
5 hospitals from 5 Spanish cities (Granada, Madrid, Pamplona, Santander and Zaragoza) in 123 
OW/OB adolescents. The complete and detailed methodology of the EVASYON Study has 124 
been described elsewhere (11).  Briefly, the EVASYON treatment programme was conducted 125 
in small groups (8-10 participants) during 13-month including twenty visits within two 126 
specific stages: 1) Intensive intervention (9 visits): participants visited the hospitals weekly 127 
for 2 months and one-week objectives were defined; 2) Extensive intervention (11 visits): 128 
participants visited the hospital monthly during 11 months. In this stage, objectives for the 129 
adolescents were to be accomplished in one month's time.  130 
The EVASYON intervention included calorie-restricted diet (10 to 40%), increased 131 
physical activity (at least 60 min/day 5 days a week), psychological therapy and nutritional 132 
education for these 13 months. Paediatricians explained the patients several motivational 133 
strategies, life and time management strategies including physical activity and sedentary 134 
behaviour recommendations, adequate sleep time, nutritional advice, family involvement, 135 
among others.  136 
Adolescents included in the EVASYON treatment met the inclusion criteria for 137 
participating: i) To be aged 13 to 16 years; ii) To be OW/OB in agreement with the 138 
International Obesity Task Force age- and sex-specific body mass index (kg/m
2
, BMI) values 139 
(12); iii) To be Spanish or to have been educated in Spain; iv) To be free of other diagnosed 140 
disease. Moreover, adolescents in pharmacological treatment or diagnosed with anorexia, 141 
bulimia or other eating disorder, except binge eating disorder, were excluded.  142 
In order to evaluate the long-term effect of the programme, we analyzed preliminary 143 
results corresponding to basal point (before the intervention) and after intensive and extensive 144 
phases of interventions (2+11 months) in OW/OB adolescents from the Madrid Hospital 145 
(Figure 1). A total of 31 adolescents (13 girls) finished the EVASYON programme in this 146 
Hospital. This study encompassed 13 boys and 12 girls (n=25) with valid data on 147 
anthropometry and blood samples before intervention and the end of the EVASYON 148 
treatment. These adolescents maintained an apparently good health status and did not 149 
consume any medications during the study.  150 
The study was conducted in accordance with the ethical rules of the Helsinki 151 
Declaration (Hong Kong revision, September 1989, in Edinburgh in 2000 and in Korea in 152 
2008), following the EEC Good Clinical Practice guidelines (document 111/3976/88 of July 153 
1990) and current Spanish law, which regulates clinical research in humans (Royal Decree 154 
561/1993 regarding clinical trials). Informed consent was obtained from all adolescents and 155 
their parents, and the study was approved by the local ethics committees. 156 
 157 
Anthropometry measurements  158 
Body weight was measured without shoes and with light clothing to the nearest 0.05 159 
kg by using a standard beam balance. Body height was measured using a stadiometer SECA 160 
714 (range, 60-200 cm). BMI z-scores were calculated as a function of the subject’s obesity 161 
degree when compared with BMI local reference standards (13). Skinfold thicknesses were 162 
measured on the left side of the body (14) to the nearest 0.1 mm with a skinfold caliper 163 
(Caliper Holtain; Holtain Ltd., Walles, UK) at triceps, biceps, subscapular, suprailiac, thigh, 164 
and calf. The five circumferences (arm relaxed, arm flexed, waist, hip and proximal waist) 165 
were measured in centimetres with an inelastic tape to the nearest millimetre. All the 166 
anthropometric variables were measured in order, three times and averaged. For all the 167 
anthropometric measurements, intraobserver reliability was >95% and interobserver 168 
reliability was >90%. In the present study, the sum of 6 skinfolds and waist circumference 169 
were used as indicators of total and central body fat, respectively.  170 
 171 
Resting blood pressure 172 
Blood pressure was measured using a validated digital automatic blood pressure 173 
monitor (Omron M6, Omron Health Care Co., Ltd., Kyoto, Japan) according to the 174 
International Protocol of the European Society of Hypertension (15).  175 
 176 
Blood sampling  177 
Blood samples were taken twice for each subject before and after the intervention (13-178 
month). After an overnight fast (12-hour fast), subjects went to the hospital for blood 179 
sampling at 8:00 a.m. Blood samples were collected by puncture of the cubital vein. For 180 
biochemical analyses, the blood was collected in SST-Vacutainer (BD) and serum was 181 
separated by centrifugation at 3000 rpm for 15 min at 22-24ºC, divided into aliquots, and 182 
frozen and stored at –80ºC until withdrawn for analysis.  183 
Biochemical parameters. Total cholesterol, HDL-cholesterol, triglycerides, and 184 
glucose were analysed by a biochemical autoanalyser (Olympus model AU2700). All serum 185 
analysis were performed at the end of the study, in order to have the three samples from each 186 
subject analysed in the same run, to avoid systematic errors. Coefficients of variance of lipid 187 
variables were 2% for total cholesterol, 2% for HDL-cholesterol and 3% for triacylglycerols. 188 
VLDL-cholesterol and LDL-cholesterol were calculated from existing cholesterol, HDL-189 
cholesterol, and triglycerides values (16).  190 
Appetite-controlling hormones. Serum levels of leptin, total peptide YY, insulin and 191 
adiponectin were measured by Luminex-100 IS (Integrated System: Luminex Corporation, 192 
Austin, TX, USA) using the human gut hormone multiplex immunoassay kit (HGT-68K) and 193 
Human CVD1 kit (HCVD1-67AK). The intra- and inter-assay precision coefficients of 194 
variation were: 7% and 9% respectively for leptin; 5% and 10% respectively for total peptide 195 
YY; 4% and 6% respectively for insulin; and 9% and 16% respectively for adiponectin.   196 
Serum cytokines. Determination of serum cytokines IL-1β, IL-2, IL-4, IL-5, IL-6, IL-197 
8, IL-10 and TNF- was performed on the Luminex-100 IS (Integrated System: Luminex 198 
Corporation, Austin, TX, USA) using the multiplex assay kit Linco High Sensitivity Human 199 
Cytokine Panel Lincoplex, 96 Well Plate Assay (HSCYTO-60SK), manufactured by Linco 200 
Research, Inc., MO, USA. Multianalyte profiling calibration microspheres for classification 201 
and reporter readings, as well as sheath fluid were also purchased from Luminex Corporation. 202 
Acquired fluorescence data were analyzed by the Luminex-100 IS v.2.3. All analyses were 203 
performed according to the manufacturer's protocols. The intra- and inter-assay precision 204 
coefficients of variation were: 3% and 2%, respectively for IL-1β; 4% and 8%, respectively 205 
for IL-2; 4% and 9%, respectively for IL-4; 5% and 14%, respectively for IL-5; 4% and 5%, 206 
respectively for IL-6; respectively for IL-8; 3% and 12%, respectively for IL-10; and 4%, 207 
respectively for TNF-.  208 
 209 
Statistical analyses 210 
Data were assessed for normality and homogeneity of variance, and are expressed as 211 
mean ± standard deviation (SD). Student’s t test was used to compare means between before 212 
and after intervention (13-month). Due to non-normal distribution, the Wilcoxon test was 213 
applied to appetite-controlling hormones and cytokine values to compare means between 214 
before and after intervention. Effect sizes (ES) were also calculated using Cohen's d as a 215 
measure of ES that reflects the magnitude of the difference between groups in SD units. 216 
Cohen's d is computed by subtracting the average score for the control group (before the 217 
intervention) from the average score for the treatment group (after the EVASYON treatment 218 
programme), and then dividing the difference by the SD on the outcome measure for the 219 
sample (17). We used the standard criteria for ES of small (d=0.20), medium (d=0.50), and 220 
large effects (d=0.80). We employed these criteria along with the results of the statistical tests 221 
in evaluating the impact of the previous results of EVASYON programme presented in the 222 
present work. Analysis was performed using SPSS software v.17. Statistical significance was 223 
set at P<0.05. 224 
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RESULTS 243 
Adolescents included in the final analysis were 14.1 ± 1.1 years old, and the 244 
prevalence of obesity at baseline was 72% (10 boys and 8 girls). These subjects showed 245 
marked differences in body fat characteristics after the intervention programme (Table 1). 246 
Thus, significant decreases in BMI mean values (–6.8%) and BMI z-score (–28.0%) were 247 
found after the intervention (all P<0.05). Levels of body fat measured by anthropometry at 248 
triceps, biceps, subscapular, thigh, and calf also decreased after the intervention (all P<0.05). 249 
The main indicators of total and central body fat, that is, the sum of 6 skinfolds (–17.8%) and 250 
waist circumference (–3.8%), also significantly decreased after the intervention (both 251 
P<0.05).  252 
Regarding cardiometabolic risk factors included in the metabolic syndrome definition 253 
(Table 2), a more favourable profile was found in all of them, but only diastolic blood 254 
pressure (–7.6%) significantly decreased after the intervention programme (P=0.018). No 255 
significant changes on adiponectin, total peptide YY and insulin levels were observed after 256 
the intervention (Table 3). In contrast, a decrease (P<0.001) on serum leptin levels (–48.4%) 257 
was found after the intervention (Table 3). Levels of IL-8 (–34.4%), IL-10 (–39.8%) and 258 
TNF- (–21.5%) also significantly decreased (all P<0.05) after the intervention programme 259 
(Table 4).  260 
 261 
 262 
 263 
 264 
 265 
 266 
 267 
DISCUSSION 268 
These preliminary results of the EVASYON treatment programme indicate a clinically 269 
relevant body fat reduction after the intervention programme in adolescents with OW/OB. 270 
This outcome has been observed mainly in the sum of 6 skinfolds (large ES) as an indicator of 271 
total body fat. Adolescence is characterised by an intense growth and development and in this 272 
sense, it is important to stress the fact that although body weight did not decrease after 273 
intervention, the decrease in BMI values observed is attributable to the increase in the body 274 
height observed. These results also point out that in adolescents with OW/OB, the 275 
improvement of body composition induced by the EVASYON intervention programme was 276 
concomitant with decreased serum concentrations of leptin, IL-8, IL-10 and TNF-.  277 
High serum leptin levels have been positively correlated with the components of the 278 
metabolic syndrome in obesity during adolescence (18,19). The reduction of leptin levels 279 
observed in the present study after body composition improvement is in agreement with other 280 
trials (20,21). Although these studies did not evaluate the ES, the leptin decrease observed 281 
after the EVASYON treatment programme showed a medium to large ES. Elloumi and co-282 
workers (20) evaluated the effect of 2-month weight-loss programme (based on energy 283 
restriction and training at the point of maximum lipid oxidation) on plasma levels of 284 
adiponectin and leptin, in 21 obese adolescent boys. The authors found that the adolescents 285 
who improved their body composition showed an increase in plasma adiponectin 286 
concentrations (+74%) and a decrease in plasma leptin levels (–39%). In addition, a decrease 287 
in plasma leptin levels (–70%) together with an increase in plasma adiponectin concentrations 288 
(+27%) have been found after a 9-month multidisciplinary weight-reduction programme with 289 
lifestyle education, moderate energy restriction and regular physical activity (21). Likewise, 290 
our results have not reflected the increase in adiponectin levels previously reported by these 291 
two studies and others (20-23), and seem to be in disagreement with the favourable body 292 
composition changes observed after the intervention programme. 293 
On the other hand, high means of BMI and waist circumference values have been 294 
highly associated with elevated circulating levels of IL-6 and IL-8 (24). Since elevated levels 295 
of pro-inflammatory cytokines correlate with obesity in adolescents confirming the presence 296 
of early phases of atherosclerosis risk (25), the decrease in serum IL-8 and TNF- 297 
concentrations (medium to large ES) observed in the current study after the intervention, 298 
might suggest an attenuation of inflammation related risk factors.  299 
To our knowledge, only a small number of studies concerning changes on serum 300 
cytokine levels after intervention obesity programmes in adolescents are available. Thus, a 301 
significant decrease in circulating IL-6 levels (–48%), associated with weight loss and 302 
reduction of fat mass, have been reported (26) after short-term (3 weeks) under energy 303 
restriction and exercise programme, in 49 obese adolescents. On the contrary, our results have 304 
not reflected a significant decrease in IL-6 levels (–36%) after the intervention programme. 305 
This conflicting outcome might be due to, for example, the differences in (i) the duration of 306 
the interventions (3-week vs 13-month); (ii) IL-6 levels at baseline (3.9±4.7 vs 3.3±3.0 307 
pg/mL); (iii) laboratory methods (ELISA vs Luminex); (iv) and sample sizes (49 vs 25 308 
adolescents).  309 
Although several authors have found no changes in TNF- in obese adolescents or 310 
adults after weight loss (27-29), other studies in adults are in agreement with our results 311 
showing decreased TNF- levels after weight loss (30-34). The release of pro-inflammatory 312 
biomarkers might be one mechanism through which obesity is linked to increased leptin 313 
values (7,10), and the current study concur with this hypothesis since leptin decreases were 314 
concurrent with IL-8 and TNF- decreases after intervention.  315 
Another conflicting finding in the present study is the decreased IL-10 levels observed 316 
after our intervention programme. On the contrary, increased serum IL-10 levels have been 317 
found after weight loss in obese adults (35). Since activated adipose tissue increases the 318 
synthesis of pro-inflammatory cytokines while regulatory cytokines, such as IL-10 are 319 
decreased (36); the decrease in IL-10 values observed after intervention seems to be 320 
contradictory. In any case, no studies evaluating IL-10 cytokine after a weight loss 321 
programme are available in adolescents. 322 
Our results have shown relevant results. Obese subjects go on to display a 323 
characteristic profile of hypertension, reduced HDL-cholesterol, and increased levels of LDL-324 
cholesterol, triglycerides, and insulin resistance (metabolic syndrome), even during childhood 325 
(37-39). In another study, after two-months of a physical-endurance and diet-restriction 326 
programme in 24 obese adolescent boys, reductions in BMI and waist circumference (–13%) 327 
were associated with decreased plasma triglycerides, LDL-cholesterol and total cholesterol 328 
levels (40). Although a decrease in diastolic blood pressure was observed, the present study 329 
has not reflected changes on cardiometabolic risk factors such as systolic blood pressure and 330 
lipid profile after body composition reduction. The different findings found among studies 331 
might be partially explained by the specific characteristics of each study (e.g. study duration, 332 
sample size) as commented above. For example, other authors have detected an improvement 333 
on lipid profile after decreasing BMI in 37 obese children who participated in a 12-month 334 
intervention programme called "Obeldicks" (41). Although the duration of this programme 335 
was one year, in this case, the age differences of the subjects involved in each study (mean 336 
age 11 vs 14 years) could support the differences between their lipid profile results and our 337 
current findings.  338 
The novelty of the current study is that it is the first long-term study (13-month) 339 
concerning the relationships between serum gut appetite-controlling hormones, serum 340 
cytokines and changes in body composition in OW/OB adolescents. One limitation of the 341 
present study includes the relative small sample size which could reduce the significance of 342 
the detected changes and the ES. In addition, body fat was obtained by anthropometric 343 
measurements and other methods (e.g. dual energy X-ray absorptiometry, air displacement 344 
plethysmography, bioelectric impedance) may be more accurate for assessing body 345 
composition changes. In any case, these preliminary results point out to a prominent body fat 346 
reduction after the intervention programme, suggesting the potential usefulness of 347 
implementing the EVASYON intervention programme for weight management in adolescents 348 
with OW/OB. Future studies including the whole sample recruited in the EVASYON study 349 
must analyse the role of important determinants (e.g. sexual maturation, socioeconomic 350 
status, gene-environmental interactions) on the changes in body fat and cardiometabolic risks 351 
during the EVASYON treatment programme. 352 
In conclusion, our preliminary results indicate that the EVASYON programme may 353 
produce moderate to large treatment effects for body fat reduction in adolescents with 354 
OW/OB. Although the body composition improvement did not improve all the classic 355 
metabolic syndrome components, these preliminary results suggest that the EVASYON 356 
programme may reduce earlier cardiometabolic risk factors such as leptin, IL-8 and TNF- 357 
levels, contributing to prevent future cardiovascular events. Nevertheless, further research is 358 
required to examine whether this improvement in the inhibition of cardiometabolic risk 359 
factors (mainly by an earlier decline in low-grade systemic inflammation) will eventually lead 360 
to a clinical benefit associated with an improvement on body composition in children and 361 
adolescents.  362 
 363 
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EXTENSIVE 
 INTERVENTION  
(10th-20th visit) 
1 visit monthly 
(11 months) 
INTENSIVE 
 INTERVENTION  
(1st-9th visit) 
1 visit weekly 
(2 months) 
RECRUITMENT IN 
A HOSPITAL FROM 
MADRID HEALTH 
CARE SERVICE 
GROUP I 
n=6 
 (3 girls) 
GROUP II 
n=7 
 (2 girls) 
GROUP III 
n=9 
(5 girls) 
GROUP IV 
n=9 
(3 girls) 
EVASYON treatment programme 
n=35 
(15 girls) 
EVASYON Inclusion/Exclusion criteria 
Adolescents in Madrid with 
overweight or obesity 
Screening 
N=42 
(16 girls) 
GROUP I 
n=6 
(3 girls) 
GROUP II 
n=9 
(2 girls) 
GROUP III 
n=10 
(6 girls) 
GROUP IV 
n=10 
(4 girls) 
Table 1. Anthropometric measurements before (baseline) and after the intervention (n=25) 
 
 
 
Before the 
intervention 
After the EVASYON 
treatment programme 
Cohen's d 
Weight (kg)   87.0 ± 14.6         84.7 ± 16.5 0.15 
Height (cm)        166.3 ± 7.1 170.4 ± 7.7*** 0.56 
BMI (kg/m
2
)
 
31.4 ± 4.4   29.2 ± 5.0*** 0.47 
BMI z-score
 
  4.7 ± 1.9     3.4 ± 1.9*** 0.70 
Biceps skinfold (mm) 18.6 ± 5.1 13.4 ± 5.5** 0.99 
Triceps skinfold (mm) 26.1 ± 3.4 22.6 ± 7.0** 0.64 
Subscapular skinfold (mm) 29.0 ± 8.6         25.3 ± 8.3* 0.44 
Suprailiac skinfold (mm) 29.3 ± 3.5         27.0 ± 7.2 0.41 
Thigh skinfold (mm) 37.2 ± 3.4   30.2 ± 8.1*** 1.14 
Calf skinfold (mm) 37.5 ± 4.7   28.2 ± 5.9*** 1.74 
Sum of 6 skindfolds (mm) 177.9 ± 18.8   147.0 ± 36.2*** 1.08 
Arm circumference (cm)        35.08 ± 3.6 33.4 ± 5.0** 0.40 
Flexed arm circumference (cm) 35.8 ± 3.6 34.6 ± 4.9** 0.28 
Waist circumference (cm) 101.2 ± 10.4 97.4 ± 13.5* 0.31 
Hip circumference (cm) 112.6 ± 11.5 108.6 ± 11.0** 0.36 
Proximal thigh circumference (cm) 70.4 ± 6.4 67.8 ± 7.7** 0.36 
 
Values expressed as mean  SD values.  *P<0.05, **P<0.01, ***P<0.001, denotes statistical 
significance between baseline and after the intervention. Student’s t test.  
 
 
Table 2. Cardiometabolic risk factors before (baseline) and after the intervention (n=25) 
 
 
 
Before the 
intervention 
After the EVASYON 
treatment programme 
Cohen's d 
Fasting glucose (mg/dL) 98.4 ± 8.1 95.9 ± 5.8 0.35 
Total cholesterol (mg/dL) 146.2 ± 23.2         143.8 ± 24.6 0.10 
Triglycerides (mg/dL)   56.7 ± 22.6    53.3 ± 31.1 0.13 
HDL-Cholesterol (mg/dL)   45.1 ± 10.1    45.8 ± 10.4 0.07 
LDL- Cholesterol (mg/dL)   89.8 ± 18.4    87.3 ± 17.5 0.14 
Systolic blood pressure (mm Hg) 130.4 ± 17.6         127.4 ± 3.8 0.24 
Diastolic blood pressure (mm Hg) 70.2 ± 8.8    65.4 ± 5.4* 0.67 
 
Values expressed as mean  SD values. *P<0.05, denotes statistical significance between 
baseline and after the intervention. Student’s t test.  
 
 
 
 
 
 
 
 
 
 
 
Table 3. Serum appetite-controlling hormones before (baseline) and after the intervention 
(n=25) 
 
 
 Before the 
intervention 
After the EVASYON 
treatment programme 
Cohen's d 
Leptin (ng/mL) 22.0 ± 12.0    14.1 ± 10.1 * 0.71 
Insulin  (pg/mL) 488.6 ± 366.7 490.7 ± 444.2 0.01 
Total peptide YY (pg/mL) 89.6 ± 47.0 87.6 ± 58.1 0.04 
Adiponectin  (ng/mL) 5.5 ± 8.7 5.4 ± 8.4 0.01 
 
Values expressed as mean  SD values. *P<0.05, denotes statistical significance between 
baseline and after the intervention. Wilcoxon test.  
 
 
 
 
 
 
 
 
 
 
 
 
Table 4. Serum cytokines before (baseline) and after the intervention (n=25) 
 
 
 
 
Before the 
intervention 
After the EVASYON 
treatment programme 
Cohen's d 
IL-1β (pg/mL) 1.1 ± 2.8 0.6 ± 1.2 0.21 
IL-2 (pg/mL) 3.0 ± 5.3 2.2 ± 4.6 0.17 
IL-6 (pg/mL) 3.3 ± 3.0 2.1 ± 1.4 0.50 
IL-4 (pg/mL) 5.2 ± 4.7 4.8 ± 3.9 0.10 
IL-8 (pg/mL)        10.0 ± 6.2   6.5 ± 3.8 * 0.66 
IL-10 (pg/mL)        17.6 ± 9.0 13.4 ± 6.7 * 0.52 
TNF-α (pg/mL)        10.2 ± 4.4   8.0 ± 2.7 * 0.60 
 
Values expressed as mean  SD values. TNF-α: tumour necrosis factor-α. *P<0.05, denotes 
statistical significance between baseline and after the intervention. Wilcoxon test.  
 
 
 
 
